Related Experiment Video

Updated: Mar 22, 2026

Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids
11:59

Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids

Published on: May 15, 2019

10.3K

Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015)

Yan-Ting Wang1, Chang-Hong Liu1, Hai-Liang Zhu1

  • 1a State Key Laboratory of Pharmaceutical Biotechnology , Nanjing University , Nanjing , P. R. China.

Expert Opinion on Therapeutic Patents
|April 26, 2016
PubMed
Abstract

Insights

Fatty acid binding proteins (FABP) inhibitors show promise for treating obesity, diabetes, and atherosclerosis. Research is ongoing to develop more effective and specific FABP inhibitors for various health conditions.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medical Chemistry

Background:

  • Obesity, diabetes, atherosclerosis, hypertension, dyslipidemia, and metabolic syndrome are significant health concerns.
  • Excessive free fatty acids (FFA) are implicated as a pathogenic factor in these diseases.
  • Fatty acid binding proteins (FABPs) are crucial for FFA transport and cellular function.

Purpose of the Study:

  • To review the applications of FABP inhibitors in preventing and treating obesity, atherosclerosis, diabetes, and metabolic syndrome.
  • To provide a comprehensive overview of patents related to FABP inhibitors from 2012 to 2015.

Main Methods:

  • Literature review focusing on FABP inhibitors.
  • Analysis of patent literature from 2012-2015.

Main Results:

  • FABP inhibitors represent a potential therapeutic strategy for metabolic diseases.
  • Significant advancements have been made in developing FABP inhibitors.
  • Novel FABP inhibitors with enhanced activity and specificity are continually being developed.

Conclusions:

  • FABP is a validated therapeutic target for obesity, atherosclerosis, diabetes, and metabolic syndrome.
  • FABP inhibitors are progressing as potential treatments for these conditions.
  • FABP inhibitors may also have applications in anti-cancer and neurological regulation.
Keywords:
FABPObesityatherosclerosisdiabetesinhibitorsinsulin resistancemetabolic syndrometarget

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.7K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
319
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
695
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
657
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.0K
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.7K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
304